Medicine Man Technologies Stock (OTC: SHWZ)

Medicine Man Technologies Stock (OTC:SHWZ), Trade Ideas

Medicine Man Technologies

Medicine Man Technologies Inc is a vertically integrated multi-state cannabis operator focused on growth through expansion into existing and new markets. The Company's business involves the cultivation, manufacturing, distribution, and retail sale of cannabis and cannabis-related products. The Company sells products it manufactures and cultivates and a variety of other cannabis goods through wholly-owned retail stores, licensing arrangements, and/or third-party operators and retailers. Its operations are organized into three different segments: Retail, consisting of retail locations for sale of cannabis products; Wholesale, consisting of manufacturing, cultivation, and sale of both wholesale cannabis and non-cannabis products; and Other, consisting of all other income and expenses.

hunters-race-MYbhN8KaaEc-unsplash(9)

Cannabis

News

Movers

BLOZF

CBIH

CMPS

CSE:BLO

CSE:GWAY

CSE:IAN

CSE:JSDA

CSE:JUSH

DBCCF

GWAYF

ITHUF

JSDA

JUSHI HLDGS INC CL B by Jushi Holdings Inc.

JUSHF

SHWZ

TSXV:DB

TSXV:HASH

Who&#39;s Who In Cannabis: Latest Executive Changes You Should Know About

AI Generated Image 

Analyst Color

Penny Stocks

Guidance

Emerging Markets

Financing

Small Cap

Management

Success Stories

Markets

Analyst Ratings

Trading Ideas

AAWH

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

Recent data from the Viridian Cannabis Deal Tracker highlights significant changes in the valuation multiples of major multi-state operators (MSOs) in the cannabis sector.

The Viridian Cannabis Deal Tracker has become an indispensable tool for companies, investors and acquirers in the cannabis industry.

Marijuana Investors Bet Big On Long-Term Growth Over Short-Term Earnings As Market Value Rises By 39%

Equities

Government

Regulations

Legal

AYRWF

GLASF

TCNNF

A recent analysis by Viridian Capital Advisors provides intriguing insights into the liquidity of cannabis companies, indicating both advancements and setbacks in the sector.

Cannabis Market&#39;s Trading Volume Surges Up 292%, Viridian Capital Highlights Mixed Liquidity

MEDICINE MAN TECH INC by Medicine Man Technologies Inc.

Medicine Man Technologies Inc

Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) reported quarterly earnings of $0.76 per share which beat the analyst consensus estimate of $0.74 by 2.7 percent. This is a 5.56 percent increase over earnings of $0.72 per share from the same period last year. The company reported quarterly sales of $5.804 billion which beat the analyst consensus estimate of $5.668 billion by 2.39 percent. This is a 2.24 percent increase over sales of $5.677 billion the same period last year.

Earnings

Earnings Beats

Halliburton Q1 2024 Adj EPS $0.76 Beats $0.74 Estimate, Sales $5.804B Beat $5.668B Estimate

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) reported quarterly earnings of $2.04 per share which beat the analyst consensus estimate of $1.86 by 9.68 percent. This is unchanged from the same period last year. The company reported quarterly sales of $2.366 billion which beat the analyst consensus estimate of $2.287 billion by 3.46 percent. This is a 1.50 percent increase over sales of $2.331 billion the same period last year.

Quest Diagnostics Q1 2024 Adj EPS $2.04 Beats $1.86 Estimate, Sales $2.366B Beat $2.287B Estimate

MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) reported quarterly earnings of $3.52 per share which beat the analyst consensus estimate of $3.45 by 2.03 percent. This is a 12.1 percent increase over earnings of $3.14 per share from the same period last year. The company reported quarterly sales of $679.965 million which missed the analyst consensus estimate of $684.135 million by 0.61 percent. This is a 14.82 percent increase over sales of $592.218 million the same period last year.

Earnings Misses

MSCI

MSCI Q1 2024 Adj EPS $3.52 Beats $3.45 Estimate, Sales $679.965M Miss $684.135M Estimate

WIIM

PENN

PENN Entertainment shares are trading higher after Truist Securities upgraded the stock from Hold to Buy.

GE Aerospace  shares are trading higher following Q1 financial results.

STLA

Shares of automakers are trading higher after General Motors raised its 2024 financial outlook.

JBLU

JetBlue Airways shares are trading lower after the company reported Q1 financial results and issued worse-than-expected Q2 and FY24 Revenue outlook.

Truist Securities analyst Nicole Germino initiates coverage on Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy rating and announces Price Target of $48.

Price Target

Initiation

INSM

Truist Securities Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $48

Xerox Holdings Corp shares are trading lower after the company reported worse-than-expected Q1 results and reiterated FY24 guidance.

General

Ermenegildo Zegna Posts 8% Y/Y Increase In Q1 Revenue To €463.2M

Truist Securities analyst Barry Jonas upgrades PENN Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) from Hold to Buy and maintains the price target from $23 to $23.

Upgrades

Truist Securities Upgrades PENN Entertainment to Buy, Maintains Price Target to $23

IBRX

ImmunityBio shares are trading higher after the company announced FDA approval of ANKTIVA.

<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
Second Quarter and Full Year 2024 Outlook
</td>
<td colspan="1" rowspan="1">
Estimated 2Q 2024
</td>
<td colspan="1" rowspan="1">
Estimated FY 2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Available Seat Miles (&quot;ASMs&quot;) Year-Over-Year
</td>
<td colspan="1" rowspan="1">
(5.0%) - (2.0%)
</td>
<td colspan="1" rowspan="1">
Down low single digits
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Revenue Year-Over-Year
</td>
<td colspan="1" rowspan="1">
(10.5%) - (6.5%)
</td>
<td colspan="1" rowspan="1">
Down low single digits
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
CASM Ex-Fuel (1) Year-Over-Year (2)
</td>
<td colspan="1" rowspan="1">
5.5% - 7.5%
</td>
<td colspan="1" rowspan="1">
Up mid-to-high single digits
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Fuel Price per Gallon (3), (4)
</td>
<td colspan="1" rowspan="1">
$2.98 - $3.13
</td>
<td colspan="1" rowspan="1">
-
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Capital Expenditures
</td>
<td colspan="1" rowspan="1">
~$550 million
</td>
<td colspan="1" rowspan="1">
~$1.6 billion
</td>
</tr>
</tbody>
</table>

JetBlue Airways Capex Outlook: Q2 ~$550M, FY24 ~$1.6B

Elon Musk, CEO of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), has given a nod of approval to ARK Invest&#8217;s analysis of the company&#8217;s Q1 expectations.
What Happened: Musk acknowledged ARK Invest&#8217;s analysis of Tesla&#8217;s Q1 expectations by commenting &#8220;Accurate&#8221; on Tasha Keeney&#8216;s interview with CNBC&#8217;s Last Call, posted on social media platform X on Tuesday.
ARK Invest&#8217;s Director of Investment Analysis &amp; Institutional Strategies, Tasha Keeney, expressed her views, stating, &#8220;I wouldn&#8217;t be surprised about some short-term upsets, but I think the long-term story is EVs are here to stay. Tesla&#8217;s prices are so competitive. It&#8217;s going to be very hard for any other company to catch up to them at this point.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Accurate
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1782634001271816516?ref_src=twsrc%5Etfw">April 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
ARK Invest has set a price target for Tesla at $2000 by 2027.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38348301/bitcoin-halving-elon-musks-dogecoin-tweet-solanas-rise-and-more-this-week-in-cryptocurrenc?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin Halving, Elon Musk&#8217;s Dogecoin Tweet, Solana&#8217;s Rise And More: This Week In Cryptocurrency</a>
Why It Matters: This comes ahead of Tesla&#8217;s Q1 earnings, which are due to be released on Tuesday. The company&#8217;s stock has been the subject of much speculation and activity recently. 
ARK Invest, led by Cathie Wood, made significant trades involving Tesla on Monday, acquiring <a href="https://www.benzinga.com/markets/equities/24/04/38368840/cathie-woods-ark-invest-seizes-tesla-dip-acquires-over-17m-in-shares-ahead-of-q1-results-zoom-st">over $17 million in shares</a>. 
Earlier, this month the company reported that it delivered 386,810 vehicles in <a href="https://www.benzinga.com/markets/equities/24/04/38047077/tesla-stock-dives-as-q1-deliveries-disappoint-but-ev-giant-reclaims-top-spot-from-chinese-rival">the first quarter</a>, down from 422,875 a year earlier. Production figures were also lower, at 433,371 compared to 440,808 units in the year-ago period. This marks Tesla's first year-over-year decline in deliveries since pandemic-hit 2020.
Analysts are also cautious about Tesla&#8217;s Q1 earnings, with some questioning whether the company is still a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38367087/tesla-q1-earnings-preview-is-ev-giant-no-longer-a-growth-stock-analysts-cautious-wa">growth stock</a>. The company has also faced internal challenges, including recent <a href="https://www.benzinga.com/news/24/04/38361822/tesla-layoffs-hit-marketing-team-retracts-advertising-push">layoffs in its marketing</a> team.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38346682/shiba-inu-army-cheers-as-burn-rate-soars-172-price-rebounds?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Shiba Inu Army Cheers As Burn Rate Soars 172%, Price Rebounds</a>
Image Via Shutterstock 
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Kaustubh Bagalkote</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/topic/kaustubh-bagalkote" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Global

Tech

TSLA

Elon Musk Reacts As ARK Invest Analyst Says 'It's Going To Be Very Hard' For Tesla Rivals 'To Catch Up To Them' In Pricing: 'Accurate'

2024 Guidance
<ul>
<li>Revenue: decline of 3% to 5% in constant currency</li>
<li>Adjusted Operating Margin: at least 7.5%</li>
<li>Free cash flow: at least $600 million</li>
</ul>

Xerox Holdings Corp Reiterated FY24 Revenue Decline of 3%-5% in Constant Currency Vs $6.59B Est

JetBlue Airways Revenue Growth Outlook: Q2 (10.5%) - (6.5%), FY24 Down Low Single Digits

Baird analyst Timothy Wojs maintains Simpson Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) with a Outperform and lowers the price target from $215 to $208.

Baird Maintains Outperform on Simpson Manufacturing Co, Lowers Price Target to $208

iQiyi Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>), often referred to as China&#8217;s Netflix, is adapting its strategy to cater to the country&#8217;s aging population. The company is also leveraging artificial intelligence (AI) to enhance its content production.
What Happened: iQiyi&#8217;s CEO and founder, Gong Yu, announced at the company&#8217;s annual conference on Tuesday that the platform is reorienting its focus towards older users, <a href="https://www.cnbc.com/2024/04/23/chinas-netflix-iqiyi-pivots-toward-an-aging-population-in-an-ai-era.html">reported</a> CNBC. Gong highlighted the challenges faced by older users, such as eyesight deterioration due to increased screen time.
He also pointed out that by 2033, a quarter of China&#8217;s population will be considered elderly, a figure that is expected to rise to a third by 2053. With the country&#8217;s aging population, iQiyi is looking to improve its content quality for children, as fewer children are being born in China.
See Also: <a href="https://www.benzinga.com/markets/asia/24/04/38369354/nvidias-high-end-chips-ended-up-in-chinese-hands-despite-us-ban-heres-how-beijing-scored-them?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s High-End Chips Ended Up In Chinese Hands Despite US Ban: Here&#8217;s How Beijing Scored Them</a>
Additionally, iQiyi is integrating AI tools into its content production process. The company&#8217;s Chief Technology Officer, Liu Wenfeng, demonstrated the platform&#8217;s AI capabilities, which can quickly replicate multi-camera shots in a virtual environment and analyze novels for production-worthy stories.
This shift in strategy comes at a time when iQiyi is looking to expand its business in overseas markets as growth in China moderates. The company, which went public in the U.S. in 2018, reported a profit for the first time in 2023, after posting annual losses of $1 billion or more for several years.
Why It Matters: The shift in iQiyi&#8217;s strategy reflects the changing demographics in China, with an increasing number of elderly citizens. This move also aligns with the broader trend of AI integration in the entertainment industry.
Earlier in April, Adobe Inc. announced the development of an <a href="https://www.benzinga.com/news/24/04/38275099/adobes-latest-ai-innovation-promises-a-new-era-for-video-content-creation">AI model for generating video content</a>, positioning itself in competition with other major players like OpenAI&#8216;s Sora and Google&#8217;s Imagen 2 in the generative AI video technology field.
However, AI&#8217;s disruptive potential has also <a href="https://www.benzinga.com/general/24/02/37400098/billionaire-tyler-perry-pauses-880-million-studio-expansion-because-of-ai-video-platform-sora-from-o">led to challenges</a>, as seen with filmmaker Tyler Perry putting his studio expansion plans on hold due to the threat from AI-powered tools like Sora.
Companies like Netflix are also adapting their strategies to cater to changing consumer preferences and technological advancements. Netflix recently reported a <a href="https://www.benzinga.com/24/04/38363616/netflix-shatters-earnings-expectations-with-surprising-revenue-reveal-and-soaring-subscriber-surge-b">surge in subscriber numbers</a>, indicating the growing demand for streaming services.
Read Next: <a href="https://www.benzinga.com/markets/asia/24/04/38346345/chinese-hackers-may-control-your-water-and-are-laying-in-wait-fbi-warns-3-startups-to-watch?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Chinese Hackers Could Control Your Water — And Are Laying in Wait: FBI</a>
Image via Shutterstock
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Kaustubh Bagalkote</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/topic/kaustubh-bagalkote" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Entertainment

Media

'China's Netflix' Wants To Woo Aging Population With AI Content After Turning Profitable

Elon Musk&#8216;s SpaceX has reported injury rates that surpass the industry average for the second consecutive year. This could potentially raise concerns for the company&#8217;s clients, including NASA.
What Happened: Recent safety data submitted to U.S. regulators by SpaceX revealed that the company&#8217;s injury rates in 2023 were higher than the industry average, Reuters reported.
The data, newly disclosed by the Occupational Safety and Health Administration (OSHA), also indicates a worsening trend in injury rates at some SpaceX facilities compared to 2022.
At SpaceX&#8217;s Brownsville, Texas manufacturing-and-launch facility, the reported injury rate was 5.9 per 100 workers, exceeding the 2022 rate of 4.8 and the industry average of 0.8. 
This follows a previous Reuters investigation that uncovered over 600 unreported worker injuries at SpaceX, including incidents resulting in crushed limbs, amputations, severe head injuries, and a fatality.
&#8220;NASA should be concerned about the quality of the work,&#8221; said David Michaels, a former OSHA administrator who is now a professor at George Washington University. High injury rates, he added, can be &#8220;an indicator of poor production quality.&#8221;
See Also: <a href="https://www.benzinga.com/markets/equities/24/04/38350014/elon-musk-reacts-to-teslas-pricing-debate-only-a-fool-thinks?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts To Tesla&#8217;s Pricing Debate: &#8216;Only A Fool Thinks ….&#8217;</a>
SpaceX did not immediately respond to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga</a>'s request for comment.
Why It Matters: This news comes at a time when Musk&#8217;s influence in the space industry is under the spotlight. Just a day before this report, Walter Isaacson, <a href="https://www.benzinga.com/general/24/04/38355446/elon-musk-is-the-only-person-able-to-get-us-astronauts-to-orbit-nasa-can-no-longer-do-it-boeing-cant">a prominent biographer, pointed out</a> Musk&#8217;s unique position in U.S. space exploration, stating that Musk is the only person capable of launching U.S. astronauts into orbit, a task that neither NASA nor Boeing can currently accomplish.
However, this revelation about SpaceX&#8217;s injury rates raises questions about the company&#8217;s operational standards, especially in light of previous safety concerns. In February, <a href="https://www.benzinga.com/news/24/02/37114481/elon-musks-spacex-fined-over-safety-violations-following-near-amputation-incident-report">SpaceX was fined $3,600</a> by U.S. worker safety officials following a near amputation incident at its Washington site. This incident was part of a series of safety violations and injuries that had been previously unreported.
Moreover, Musk&#8217;s other venture, The Boring Company, has also been under scrutiny for its <a href="https://www.benzinga.com/startups/24/04/38023883/i-refuse-to-be-the-first-fatality-elon-musks-the-boring-companys-safety-record-reportedly-left-emplo">poor safety record</a> and dangerous working conditions, further raising concerns about Musk&#8217;s overall approach to worker safety.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38346576/doge-day-has-an-elon-musk-connection-meme-coin-rebounds-after-the-bitcoin-halving-sell-the?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Doge Day Has An Elon Musk Connection, Meme Coin Rebounds After The Bitcoin Halving &#8216;Sell-The-News&#8217; Drop</a>
Image Via Shutterstock 
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Kaustubh Bagalkote</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/topic/kaustubh-bagalkote" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

SPACE

Elon Musk's SpaceX Injury Rates Exceed Industry Average Again, Raising Concerns For NASA And Clients: Report

The Company is affirming its full year 2024 equipment rental revenue growth, adjusted EBITDA, and gross and net rental capital expenditures&nbsp;guidance&nbsp;ranges.&nbsp;

Herc Holdings Affirms 2024 Performance Targets, Excluding Cinelease, Of 7-10% Equipment Rental Revenue Growth And Adjusted EBITDA Of $1.55B-$1.60B

In a report released today, Joe Gomes from Noble Financial maintained a Buy rating on Medicine Man Technologies (SHWZ – Research Report), with a pr...

Noble Financial Reaffirms Their Buy Rating on Medicine Man Technologies (SHWZ)

Medicine Man Technologies Q4 2023 Earnings Preview

Notable earnings after Wednesday's close

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Medicine Man Technologies (OTCMKTS:<a href="https://investorplace.com/stock-quotes/shwz-stock-quote/">SHWZ</a>) just reported results for the fourth quarter of 2023.<ul><li>Medicine Man Technologies reported earnings per share of -38 cents. This was below the analyst estimate for EPS of -13 cents.</li><li>The company reported revenue of $43.33 million.</li><li>This was 4.72% worse than the analyst estimate for revenue of $45.47 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/shwz-stock-earnings-medicine-man-technologies-for-q4-of-2023/">SHWZ Stock Earnings: Medicine Man Technologies Misses EPS, Misses Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SHWZ Stock Earnings: Medicine Man Technologies Misses EPS, Misses Revenue for Q4 2023

Medicine Man Technologies, Inc. (SHWZ) Q4 2023 Earnings Call Transcript

Benchmark Co. analyst Mike Hickey maintained a Buy rating on Medicine Man Technologies (SHWZ – Research Report) today and set a price target of $2....

Benchmark Co. Sticks to Its Buy Rating for Medicine Man Technologies (SHWZ)

Medicine Man Technologies Inc (SHWZ) reported less than expected earnings this afternoon for Q4 2023. Medicine Man Technologies Inc's earnings came in at an EPS loss of $0.38 per share, 192% lower than estimates for an EPS loss of $0.13 per share. The firm's loss per share expanded by 23% since reporting a loss of $0.31 pe

Medicine Man Technologies Inc Down 14.77% To $0.75 After Earnings Miss

Medicine Man Technologies GAAP EPS of -$0.43, revenue of $43.3M misses by $2.17M

Medicine Man Technologies (SHWZ) Receives a Buy from Noble Financial

Medicine Man Technologies, Inc. (SHWZ) has released an update. Medicine Man Technologies, Inc. has released its financial results for the fourth qu...

Medicine Man Technologies Announces Year-End Financials

AQMS

BRZE

CWCO

DRRX

GREE

LGMK

MLKN

OIBZQ

PLBY

SSKN

USIO

VNET

VRNT

Press Releases

MULTI-STATE CANNABIS OPERATOR, SCHWAZZE, CONTINUES EXPANSION IN NEW MEXICO WITH NEW R.GREENLEAF STORE OPENING IN HOBBS, NM

Schwazze Announces Second Quarter 2023 Financial Results

Schwazze Announces Third Quarter 2023 Financial Results

Schwazze Appoints Forrest Hoffmaster as Interim Chief Executive Officer

Schwazze Sets Fourth Quarter and Full Year 2023 Conference Call for March 27, 2024 at 5:00 p.m. ET

Schwazze Announces Fourth Quarter and Full Year 2023 Financial Results

Benchmark